The Effect of Anabolic Steroids on Anemia in Myelofibrosis with Myeloid Metaplasia: Retrospective Analysis of 39 Patients in Japan

  • Kazuya Shimoda
  • Kotaro Shide
  • Kenjirou Kamezaki
  • Takashi Okamura
  • Naoki Harada
  • Naoko Kinukawa
  • Kazuma Ohyashiki
  • Yoshiyuki Niho
  • Hideaki Mizoguchi
  • Mitsuhiro Omine
  • Keiya Ozawa
  • Mine Harada
Article

Abstract

Between 1999 and 2005,285 patients received new diagnoses of myelofibrosis with myeloid metaplasia (MMM) in Japan. Anemic symptoms were present in 162 patients, and hemoglobin (Hb) concentrations were <10 g/dL in 197 patients. Fifty-five MMM patients were treated with anabolic steroids, and their effect on anemia during MMM was evaluated in 39 patients. A “good” response was defined as an Hb increase of ≥1.5 g/dL, cessation of transfusion dependence, and an Hb concentration of >10 g/dL maintained for at least 8 weeks. A “minimum” response was defined as an Hb increase of ≥1.5 g/dL and transfusion independence for at least 8 weeks. Both good and minimum responses were considered “favorable.” Favorable responses were achieved in 17 patients (44%, 8 good and 9 minimum responses). None of the pretreatment variables, such as the lack of transfusion dependence, a higher Hb concentration at the start of treatment, or the absence of cytogenetic abnormalities, were associated with a response to anabolic steroid therapy. Adverse events associated with anabolic steroid therapy were moderate and transient. Two patients required definitive withdrawal of treatment. Thus, anabolic steroids are well tolerated and effective for the treatment of anemia in a subset of MMM patients.

Key words

Myelofibrosis with myeloid metaplasia Anabolic steroids Anemia Therapy 

Reference

  1. 1.
    Tefferi A. Myelofibrosis with myeloid metaplasia. N Engl J Med. 2000;342:1255–1265.PubMedCrossRefGoogle Scholar
  2. 2.
    Ihle JN, Nosaka T, Thierfelder W, Quelle FW, Shimoda K. Jaks and Stats in cytokine signaling. Stem Cells. 1997;15(suppl 1):105–111, discussion 112.PubMedCrossRefGoogle Scholar
  3. 3.
    Ihle JN. Cytokine receptor signalling. Nature. 1995;377:591–594.PubMedCrossRefGoogle Scholar
  4. 4.
    Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365:1054–1061.PubMedGoogle Scholar
  5. 5.
    James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434:1144–1148.PubMedCrossRefGoogle Scholar
  6. 6.
    Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352:1779–1790.PubMedCrossRefGoogle Scholar
  7. 7.
    Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombo- cythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7:387–397.PubMedCrossRefGoogle Scholar
  8. 8.
    Chagraoui H, Komura E, Tulliez M, Giraudier S, Vainchenker W, Wendling E. Prominent role of TGF-?1 in thrombopoietin-induced myelofibrosis in mice. Blood. 2002;100:3495–3503.PubMedCrossRefGoogle Scholar
  9. 9.
    Chagraoui H, Tulliez M, Smayra T, et al. Stimulation of osteoprote-gerin production is responsible for osteosclerosis in mice overexpressing TPO. Blood. 2003;101:2983–2989.PubMedCrossRefGoogle Scholar
  10. 10.
    Kakumitsu H, Kamezaki K, Shimoda K, et al. Transgenic mice overexpressing murine thrombopoietin develop myelofibrosis and osteosclerosis. Leuk Res. 2005;29:761–769.PubMedCrossRefGoogle Scholar
  11. 11.
    Guardiola P, Esperou H, Cazals-Hatem D, et al. Allogeneic bone marrow transplantation for agnogenic myeloid metaplasia: French Society of Bone Marrow Transplantation. Br J Haematol. 1997;98:1004–1009.PubMedCrossRefGoogle Scholar
  12. 12.
    Guardiola P, Anderson JE, Bandini G, et al, for the International Collaboration for Transplantation in Agnogenic Myeloid Metaplasia. Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European Group for Blood and Marrow Transplantation, Société Française de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center collaborative study. Blood. 1999;93: 2831–2838.PubMedGoogle Scholar
  13. 13.
    Deeg HJ, Gooley TA, Flowers ME, et al. Allogeneic hematopoietic stem cell transplantation for myelofibrosis. Blood. 2003;102: 3912–3918.PubMedCrossRefGoogle Scholar
  14. 14.
    Ditschkowski M, Beelen DW, Trenschel R, Koldehoff M, Elmaagacli AH. Outcome of allogeneic stem cell transplantation in patients with myelofibrosis. Bone Marrow Transplant. 2004;34:807–813.PubMedCrossRefGoogle Scholar
  15. 15.
    Okamura T, Kinukawa N, Niho Y, Mizoguchi H. Primary chronic myelofibrosis: clinical and prognostic evaluation in 336 Japanese patients. Int J Hematol. 2001 ;73:194–198.PubMedCrossRefGoogle Scholar
  16. 16.
    Kennedy BJ. Effect of androgenic hormone in myelofibrosis. JAMA. 1962;182:116–119.PubMedGoogle Scholar
  17. 17.
    Silver RT, Jenkins DE Jr, Engle RL Jr. Use of testosterone and busulfan in the treatment of myelofibrosis with myeloid metaplasia. Blood. 1964;23:341–353.PubMedGoogle Scholar
  18. 18.
    Hast R, Engstedt L, Jameson S, et al. Oxymetholone treatment in myelofibrosis. Blut. 1978;37:19–26.PubMedCrossRefGoogle Scholar
  19. 19.
    Besa EC, Nowell PC, Geller NL, Gardner FH. Analysis of the androgen response of 23 patients with agnogenic myeloid metaplasia: the value of chromosomal studies in predicting response and survival. Cancer. 1982;49:308–313.PubMedCrossRefGoogle Scholar
  20. 20.
    Brubaker LH, Briere J, Laszlo J, et al. Treatment of anemia in myeloproliferative disorders: a randomized study of fluoxymes-terone v transfusions only. Arch Intern Med. 1982;142:1533–1537.PubMedCrossRefGoogle Scholar
  21. 21.
    Cervantes F, Alvarez-Larran A, Domingo A, Arellano-Rodrigo E, Montserrat E. Efficacy and tolerability of danazol as a treatment for the anaemia of myelofibrosis with myeloid metaplasia: long- term results in 30 patients. Br J Haematol. 2005;129:771–775.PubMedCrossRefGoogle Scholar
  22. 22.
    Giovanni B, Michelle E, Letizia C, et al. Thalidomide in myelofibrosis with myeloid metaplasia: a pooled-analysis of individual patient data from five studies. Leuk Lymphoma. 2002;43: 2301–2307.PubMedCrossRefGoogle Scholar
  23. 23.
    Barosi G, Grossi A, Comotti B, Musto P, Gamba B, Marchetti M. Safety and efficacy of thalidomide in patients with myelofibrosis with myeloid metaplasia. Br J Haematol. 2001;114:78–83.PubMedCrossRefGoogle Scholar
  24. 24.
    Mesa RA, Steensma DP, Pardanani A, et al. A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia. Blood. 2003;101:2534–2541.PubMedCrossRefGoogle Scholar
  25. 25.
    Marchetti M, Barosi G, Balestri F, et al. Low-dose thalidomide ameliorates cytopenias and splenomegaly in myelofibrosis with myeloid metaplasia: a phase II trial. J Clin Oncol. 2004;22:424–431.PubMedCrossRefGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2007

Authors and Affiliations

  • Kazuya Shimoda
    • 1
    • 9
  • Kotaro Shide
    • 1
  • Kenjirou Kamezaki
    • 1
  • Takashi Okamura
    • 2
  • Naoki Harada
    • 1
  • Naoko Kinukawa
    • 3
  • Kazuma Ohyashiki
    • 4
  • Yoshiyuki Niho
    • 5
  • Hideaki Mizoguchi
    • 6
  • Mitsuhiro Omine
    • 7
  • Keiya Ozawa
    • 8
  • Mine Harada
    • 1
  1. 1.Medicine and Biosystemic ScienceKyushu University Graduate School of Medical SciencesFukuokaJapan
  2. 2.Department of HematologyKurume UniversityFukuokaJapan
  3. 3.Department of Medical Information ScienceKyushu University HospitalFukuokaJapan
  4. 4.Department of HematologyTokyo Medical UniversityTokyoJapan
  5. 5.Chihaya HospitalFukuokaJapan
  6. 6.Saitama Prefecture Red Cross Blood CenterSaitamaJapan
  7. 7.Department of HematologyFujigaoka Hospital, Showa UniversityKanagawaJapan
  8. 8.Division of Hematology, Department of MedicineJichi Medical SchoolTochigiJapan
  9. 9.Department of Gastroenterology and HematologyMiyazaki UniversityMiyazakiJapan

Personalised recommendations